Comment on: Brentuximab vedotin-related neuropathy in a patient with Gilbert syndrome: Do mutations of UGT1A1 gene affect brentuximab toxicity?

Pediatr Blood Cancer. 2023 Nov;70(11):e30527. doi: 10.1002/pbc.30527. Epub 2023 Jun 26.

Authors

Carla Marco¹, Ariadna Padró-Miquel², Eva Domingo-Domenech³, Roser Velasco¹

Affiliations

¹ Neuro-Oncology Unit, Department of Neurology, Hospital Universitari de Bellvitge - Institut Català d'Oncologia, IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain.
² Molecular Genetics Unit, Clinical Laboratory, Hospital Universitari de Bellvitge, IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain.
³ Department of Clinical Hematology, Institut Català d'Oncologia, Hospital Duran I Reynals, IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain.

PMID: 37365120
DOI: 10.1002/pbc.30527

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't
Comment

MeSH terms

Antibodies, Monoclonal
Antineoplastic Agents*
Brentuximab Vedotin
Gilbert Disease*
Humans
Immunoconjugates*
Mutation

Substances

Brentuximab Vedotin
Antineoplastic Agents
Antibodies, Monoclonal
Immunoconjugates